Vanda Pharmaceuticals (LTS:0LKB) ROCE %: -62.61% (As of Mar. 2026)

What is Vanda Pharmaceuticals ROCE %?

Vanda Pharmaceuticals LTS:0LKB -2.23% 71 ROCE % is -62.61% as of Mar. 2026. GuruFocus rates LTS:0LKB with a GF Score™ of 71/100 and a GF Value™ of $5.57 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vanda Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -62.61%.

Vanda Pharmaceuticals (LTS:0LKB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vanda Pharmaceuticals ROCE % Related Terms

Vanda Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals ROCE % Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

8.54

1.19

-2.53

-7.28

-33.59

Vanda Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-30.27	-29.87	-25.37	-39.03	-62.61

71GF Score

Vanda Pharmaceuticals Inc LTS:0LKB

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vanda Pharmaceuticals ROCE % Calculation

Vanda Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-151.168	/	( ( (656.204 - 99.981)	+	(488.948 - 145.162) )	/ 2 )
	=	-151.168	/	( (556.223	+	343.786)	/ 2 )
	=	-151.168	/	450.0045
	=	-33.59 %

Vanda Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-200.896	/	( ( (488.948 - 145.162)	+	(433.525 - 135.582) )	/ 2 )
	=	-200.896	/	( ( 343.786	+	297.943 )	/ 2 )
	=	-200.896	/	320.8645
	=	-62.61 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -62.61% mean?

Vanda Pharmaceuticals (LTS:0LKB) has a ROCE % of -62.61% as of Mar. 2026.

Is Vanda Pharmaceuticals' ROCE % too high?

Vanda Pharmaceuticals' current ROCE % is -62.61%. Overall, Vanda Pharmaceuticals has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Vanda Pharmaceuticals' ROCE % compare to FBRX and ARTV?

Vanda Pharmaceuticals' ROCE % of -62.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vanda Pharmaceuticals's current ROCE % is -62.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vanda Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Vanda Pharmaceuticals (LTS:0LKB) is currently considered Fairly Valued. The stock's GF Value™ is $5.57, compared to a current price of $5.91 — trading 6.1% above its estimated fair value. The current ROCE % is -62.61%. Vanda Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Vanda Pharmaceuticals (LTS:0LKB), the current ROCE % is -62.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (LTS:0LKB) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of $5.91 is trading 6.1% above its estimated GF Value™ of $5.57. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0LKB:

ROCE %: -62.61%
GF Value™: $5.57 vs. price of $5.91 (6.1% above fair value)
GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the LTS:0LKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies FBRX ARTV OABI ENTA VSTM BNTC IMRX AVIR PROK LXEO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges VNDA:USA VM4:Germany

Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037

Website https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

71GF Score

Get the complete analysis for LTS:0LKB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.91

Price

$5.57

GF Value

View LTS:0LKB Analysis

See ROCE % data for all stocks →